PHG

PHG

USD

Koninklijke Philips N.V. NY Registry Shares

$28.020-0.180 (-0.638%)

Echtzeitkurs

Healthcare
Medizinprodukte
Niederlande

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$28.200

Hoch

$28.525

Tief

$27.830

Volumen

1.00M

Unternehmensfundamentaldaten

Marktkapitalisierung

26.9B

Branche

Medizinprodukte

Land

Netherlands

Handelsstatistiken

Durchschnittliches Volumen

0.74M

Börse

NYQ

Währung

USD

52-Wochen-Spanne

Tief $21.48Aktuell $28.020Hoch $29.29

Ähnliche Nachrichten

GlobeNewswire

Philips continues momentum; delivers strong order intake, step-up in sales growth and margin expansion

November 4, 2025Q3 2025 Group Highlights Comparable order intake growth 8%Group sales amounted to EUR 4.3 billion, reflecting 3% increase in comparable salesIncome from operations was EUR 330 millionAdjusted EBITA

Mehr anzeigen
Philips continues momentum; delivers strong order intake, step-up in sales growth and margin expansion
BusinessWire

Philips Joins the Forever Promise Project to Honor American Veterans

Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced its support of the Forever Promise Project, an initiative of the Monuments Men and Women Foundation that connects American

Mehr anzeigen
Philips Joins the Forever Promise Project to Honor American Veterans
GlobeNewswire

Hoag selects Philips to enhance and unify patient monitoring, elevating care across Orange County, USA

October 30, 2025 10-year collaboration aims to connect scalable monitoring technology that streamlines workflows, supporting patient safety and the patient and clinician experienceAmsterdam, the Netherlands and Newport

Mehr anzeigen
Hoag selects Philips to enhance and unify patient monitoring, elevating care across Orange County, USA
GlobeNewswire

Late-breaking iMODERN findings presented at TCT 2025 and published in the New England Journal of Medicine highlight new evidence to guide treatment choices for heart attack patients

October 29, 2025 3-Year data from the largest global trial to date using Class I, Level A iFR in heart attack patients shows treating additional stenoses in the same procedure showed no significant difference in major

Mehr anzeigen
Late-breaking iMODERN findings presented at TCT 2025 and published in the New England Journal of Medicine highlight new evidence to guide treatment choices for heart attack patients